

Supplemental Table 1. Published pharmacokinetic studies of moxifloxacin in adults and children with tuberculosis.

Study	Disease	HIV	Age	Bodyweight (kg)	N	Mfx dose	T _{max} (h)	t _{1/2} (h)	C _{max} (µg/ml)	AUC ₀₋₂₄ (µg·h/ml)	AUC _{0-inf} (µg·h/ml)	AUC _{other} (µg·h/ml)
Adults												
Johnson JL, et al. 2006 [8]	TB	0	35 (25-37)	56 (50-60)	10	400mg orally	1.0 ^a (1.0-2.0)	8.1 ^a (5.1-9.9)	6.1 ^a (4.5-9.0)	55.3 ^a (36.0-79.1)		
Nijland HMJ, et al. 2007 [11]	TB		30 (20-55)	55 ^a (38-80)	19	400mg orally (with 450mg RMP)	2.5 ^a (0.5-6.0)	7.1 ^a (5.0-9.6)	3.2 ^a (2.5-4.5)	33.3 ^a (25.1-55.5)		
					19	400mg orally	1.0 ^a (0.5-3.0)	9.9 ^a (7.4-14.0)	4.7 ^a (3.4-6.0)	48.2 ^a (37.2-60.5)		
Peloquin CA, et al. 2008 [12]	TB		35 (18-46)	56 ^b (43-69)	9	400mg orally	1.0 ^a (1.0-2.0)	6.53 ^a (4.25-10.6)	6.13 ^a (4.5-9.0)	60 ^a (24-140)		
Pranger AD, et al. 2011 [10]	TB		adults		16	400mg orally (with and without RMP)	1 ^a (1-2)	8 ^a (6-10)	2.5 ^a (2.0-2.9)	24.9 ^a (20.7-35.2)		
Zvada SP, et al. 2012 [13]	TB		40 (21-51)	52 ^b (42-71)	27	400mg orally			3.8 ^a (2.1-4.6)		50.8 ^a (31.8-65.3)	
Manika K, et al. 2012 [14]	MDR/XDR-TB	0/7	40.1 (15.7)		7	400mg orally	2.36 ^b (0.56)		4.59 ^b (2.06)	37.96 ^b (16.5)		
Ruslami R, et al. 2013 [15]	TB-meningitis		18-60	47-50	19	400mg orally (plus RMP)	2 ^a (1-6)		3.9 ^b (3.2-4.8)	28.6 ^b (24.2-33.8)		AUC ₀₋₆ 15.1 ^b (12.8-17.7)
			18-64		16	800mg orally (plus RMP)	2 ^a (1-6)		7.4 ^b (5.6-9.6)	60.4 ^b (45.4-80.3)		AUC ₀₋₆ 28.6 ^b (24.2-33.8)

Children

Thee S, et al. (current article)	MDR	6/23	8-15	23	10mg/kg orally	2.0 ^a (1.0- 8.0)	4.14 ^a (3.5-6.1)	3.08 ^a (2.9-3.8)	23.31 ^a (19.2-42.3)	AUC ₀₋₈ 17.2 ^a (14.5-22.0)
--	-----	------	------	----	-------------------	-----------------------------------	--------------------------------	--------------------------------	-----------------------------------	---

a) reported as median (range); b) reported as mean (standard deviation)

Mfx=moxifloxacin